IntelGenx Announces Commercialization with Global Pharmaceutical Co

 

SAINT-LAURENT, CANADA – IntelGenx Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a term sheet with a global pharmaceutical company for the development and commercialization of up to three products utilizing IntelGenx’ proprietary VersaFilm™ technology. Pursuant to the term sheet, IntelGenx granted an exclusive negotiation period during which time the parties will conduct diligence and work towards entry into a definitive agreement. IntelGenx receives $100,000 at the time of signing the term sheet, in consideration for granting an exclusive negotiation right. If entered into, IntelGenx expects the definitive agreement to be finalized by the second quarter of 2016.

Subscribe to get the latest news